MedPath

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Completed
Conditions
Non Small Cell Lung Cancer
Registration Number
NCT01167972
Lead Sponsor
AstraZeneca
Brief Summary

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.

Detailed Description

MSD

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
  • Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed
Read More
Exclusion Criteria
  • Assessment of mutational status of EGFR is not done
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinomaAt baseline
Secondary Outcome Measures
NameTimeMethod
Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).12 months / At each visit
Describe the therapeutic management of patients with EGFR M +.12 months / At each visit
Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-201212 months / At each visit

Trial Locations

Locations (1)

Research Site

🇫🇷

Yerres, France

© Copyright 2025. All Rights Reserved by MedPath